The effect of SGLT-2 inhibitor use on left ventricular longitudinal strain and NT-proBNP level during six-month follow-up in diabetic patients with and without coronary artery disease with preserved ejection fraction
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution-Non-Commercial-No Derivatives 4.0 InternationalTarih
2024Yazar
Biter, Halil İbrahimÇakal, Sinem
Çakal, Beytullah
Apaydın, Ziya
Kılınç, Ali Yaşar
Oğuz, Hüseyin
Yıldız, Sinan
Oğur, Hasan
Belen, Erdal
Şimşek, Emel
Üst veri
Tüm öğe kaydını gösterKünye
Biter, H. İ., Çakal, S., Çakal, B., Apaydın, Z., Kılınç, A. Y., Oğuz, H. ... Şimsek, E. (2024). The effect of SGLT-2 inhibitor use on left ventricular longitudinal strain and NT-proBNP level during six-month follow-up in diabetic patients with and without coronary artery disease with preserved ejection fraction. Kardiologia Polska. http://dx.doi.org/10.33963/v.phj.100613Özet
Background: Optimal glycemic control is necessary in order to prevent cardiovascular events
to a large extent in patients with type 2 diabetes. The positive effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cardiovascular events and mortality in these patients have been demonstrated in previous studies, although their mechanisms are not clear. Aims: We aimed to compare the effect of SGLT2i on left ventricular remodeling and strain in diabetic patients with coronary artery disease (CAD) and without CAD during 6-month followup. Methods: Between October 2021 and June 2022, 100 diabetic patients with preserved ejection fraction (HbA1c levels 6.5–10) were started on SGLT2i (empagliflozin or dapagliflozin) and were prospectively followed-up. Conventional and speckle tracking echocardiography were performed by blinded sonographers, at baseline and 1-month, 6-month of treatment. The initial and sixth month biochemical blood tests and N-terminal pro-B-type natriuretic peptide levels of the patients were drawn. Results: Patients with CAD were older (P = 0.008), more frequently hypertensive (P = 0.035) and had dyslipidemia (P = 0.021). N-terminal pro-B-type natriuretic peptide levels did not change significantly after treatment for both groups. Left ventricular ejection fraction, global, 2-chamber and 3-chamber strain values were improved significantly following SGLTi administration for overall patient cohort, regardless of CAD status (P <0.05 for all groups). Conclusions: Treatment with SGLT2i resulted in improvement in left ventricular strain parameters indicating that they might have a positive effect on outcomes of diabetic patients with preserved EF.
Kaynak
Kardiologia PolskaKoleksiyonlar
- Makale Koleksiyonu [3804]
- PubMed İndeksli Yayınlar Koleksiyonu [4268]